Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Stock Information for Candel Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.